SCHEMBL474092

SCHEMBL474092

COC(=O)C=Cc1cccc2c1O2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
TYR P14679 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL474093 1.00 ALDH1A1 (0.46) ALDH1A1KDM4EMAPTMEN1TP53
SCHEMBL31318868 0.81 RAB9A (0.42) ALDH1A1KDM4EMAPTCYP1A2CYP2C19
SCHEMBL10474273 0.80 KDM4E (0.68) KDM4EMAPTCA1CA2MAOB
SCHEMBL10474271 0.80 KDM4E (0.68) KDM4EMAPTCA1CA2MAOB
SCHEMBL10438847 0.79 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTMEN1TP53
SCHEMBL69522 0.79 ALDH1A1 (0.58) ALDH1A1KDM4EMAPTMEN1TP53
SCHEMBL11061667 0.77 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTMEN1TP53
SCHEMBL2855381 0.74 MAPT (0.53) ALDH1A1KDM4EMAPTMEN1CYP1A2
SCHEMBL31111018 0.74 ALDH1A1 (0.38) ALDH1A1KDM4EMAPTMEN1TP53
SCHEMBL2933196 0.73 IAPP (0.67) ALDH1A1KDM4EMAPTMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348696-B1 Use of optically active clausenamides for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same INST MATERIA MEDICA CAMS (CN) 2012-02-01 EP disclosed
US-6787564-B2 FOR TREATING HYPOXIA PROTECTIVE, NOOTROPIC AND NEURODEGENERATIVE DISEASES (CERBRAL ISCHEMIA, ALZHEIMER'S DISEASE, AND VASCULAR DEMENTIA) INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2004-09-07 US disclosed
US-20030207935-A1 Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES 2003-11-06 US disclosed
EP-1348696-A1 Optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207935-A1 Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use HIF1AN, HIF1A, CLN6 ALDH1A1 1464/4885KDM4E 3778/4885MAPT 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.